Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia
Abstract Objective Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors are a new class of anti-anemia agents. We retrospectively evaluated the safety and efficacy of HIF-PH inhibitors in patients with heart failure (HF) complicated by anemia associated with chronic kidney disase. HIF-PH...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-03-01
|
| Series: | BMC Research Notes |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13104-024-06726-7 |
| _version_ | 1827328750810824704 |
|---|---|
| author | Takahiro Kambara Rei Shibata Yuusuke Sakamoto Teruhiro Sakaguchi Hiroyuki Osanai Yoshihito Nakashima Hiroshi Asano Toyoaki Murohara Masayoshi Ajioka |
| author_facet | Takahiro Kambara Rei Shibata Yuusuke Sakamoto Teruhiro Sakaguchi Hiroyuki Osanai Yoshihito Nakashima Hiroshi Asano Toyoaki Murohara Masayoshi Ajioka |
| author_sort | Takahiro Kambara |
| collection | DOAJ |
| description | Abstract Objective Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors are a new class of anti-anemia agents. We retrospectively evaluated the safety and efficacy of HIF-PH inhibitors in patients with heart failure (HF) complicated by anemia associated with chronic kidney disase. HIF-PH inhibitor treatment was initiated in 32 patients with chronic HF complicated by renal anemia and were followed up for 3 months. Results Hematocrit and hemoglobin levels markedly improved 3 months after HIF-PH inhibitor treatment. However, levels of NT-proBNP, which is an indicator of HF, did not decrease considerably. Based on the rate of change in NT-proBNP, we divided the patients into “responder” and “non-responder” groups. The results showed that considerably more patients had a ferritin level of less than 100 ng/mL in the non-responder group at baseline. There were substantially more patients with TSAT of less than 20% in the non-responder group at 1 month after HIF-PH inhibitor treatment. The cut-off values to maximize the predictive power of ferritin level at baseline and TSAT value at 1 month after treatment were 41.8 ng/ml and 20.75. HIF-PH inhibitor treatment can be expected to be effective for improving both anemia and HF if ferritin≥41.8 ng/ml at baseline or TSAT≥20.75 at 1 month after treatment. |
| first_indexed | 2024-03-07T15:21:51Z |
| format | Article |
| id | doaj.art-5c3ebe4c0b8d4e92be810fe3b7070e1e |
| institution | Directory Open Access Journal |
| issn | 1756-0500 |
| language | English |
| last_indexed | 2024-03-07T15:21:51Z |
| publishDate | 2024-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Research Notes |
| spelling | doaj.art-5c3ebe4c0b8d4e92be810fe3b7070e1e2024-03-05T17:35:36ZengBMCBMC Research Notes1756-05002024-03-011711610.1186/s13104-024-06726-7Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemiaTakahiro Kambara0Rei Shibata1Yuusuke Sakamoto2Teruhiro Sakaguchi3Hiroyuki Osanai4Yoshihito Nakashima5Hiroshi Asano6Toyoaki Murohara7Masayoshi Ajioka8Department of Cardiovascular Medicine, Tosei General HospitalDepartment of Advanced Cardiovascular Therapeutics, Nagoya University Graduate School of MedicineDepartment of Cardiovascular Medicine, Tosei General HospitalDepartment of Cardiovascular Medicine, Tosei General HospitalDepartment of Cardiovascular Medicine, Tosei General HospitalDepartment of Cardiovascular Medicine, Tosei General HospitalDepartment of Cardiovascular Medicine, Tosei General HospitalDepartment of Cardiology, Nagoya University Graduate School of MedicineDepartment of Cardiovascular Medicine, Tosei General HospitalAbstract Objective Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors are a new class of anti-anemia agents. We retrospectively evaluated the safety and efficacy of HIF-PH inhibitors in patients with heart failure (HF) complicated by anemia associated with chronic kidney disase. HIF-PH inhibitor treatment was initiated in 32 patients with chronic HF complicated by renal anemia and were followed up for 3 months. Results Hematocrit and hemoglobin levels markedly improved 3 months after HIF-PH inhibitor treatment. However, levels of NT-proBNP, which is an indicator of HF, did not decrease considerably. Based on the rate of change in NT-proBNP, we divided the patients into “responder” and “non-responder” groups. The results showed that considerably more patients had a ferritin level of less than 100 ng/mL in the non-responder group at baseline. There were substantially more patients with TSAT of less than 20% in the non-responder group at 1 month after HIF-PH inhibitor treatment. The cut-off values to maximize the predictive power of ferritin level at baseline and TSAT value at 1 month after treatment were 41.8 ng/ml and 20.75. HIF-PH inhibitor treatment can be expected to be effective for improving both anemia and HF if ferritin≥41.8 ng/ml at baseline or TSAT≥20.75 at 1 month after treatment.https://doi.org/10.1186/s13104-024-06726-7Heart failureHIF-PH inhibitorNT-proBNPRenal anemiaFerritinTSAT |
| spellingShingle | Takahiro Kambara Rei Shibata Yuusuke Sakamoto Teruhiro Sakaguchi Hiroyuki Osanai Yoshihito Nakashima Hiroshi Asano Toyoaki Murohara Masayoshi Ajioka Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia BMC Research Notes Heart failure HIF-PH inhibitor NT-proBNP Renal anemia Ferritin TSAT |
| title | Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia |
| title_full | Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia |
| title_fullStr | Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia |
| title_full_unstemmed | Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia |
| title_short | Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia |
| title_sort | impact of hif prolyl hydroxylase inhibitors in heart failure patients with renal anemia |
| topic | Heart failure HIF-PH inhibitor NT-proBNP Renal anemia Ferritin TSAT |
| url | https://doi.org/10.1186/s13104-024-06726-7 |
| work_keys_str_mv | AT takahirokambara impactofhifprolylhydroxylaseinhibitorsinheartfailurepatientswithrenalanemia AT reishibata impactofhifprolylhydroxylaseinhibitorsinheartfailurepatientswithrenalanemia AT yuusukesakamoto impactofhifprolylhydroxylaseinhibitorsinheartfailurepatientswithrenalanemia AT teruhirosakaguchi impactofhifprolylhydroxylaseinhibitorsinheartfailurepatientswithrenalanemia AT hiroyukiosanai impactofhifprolylhydroxylaseinhibitorsinheartfailurepatientswithrenalanemia AT yoshihitonakashima impactofhifprolylhydroxylaseinhibitorsinheartfailurepatientswithrenalanemia AT hiroshiasano impactofhifprolylhydroxylaseinhibitorsinheartfailurepatientswithrenalanemia AT toyoakimurohara impactofhifprolylhydroxylaseinhibitorsinheartfailurepatientswithrenalanemia AT masayoshiajioka impactofhifprolylhydroxylaseinhibitorsinheartfailurepatientswithrenalanemia |